Newswise — The Fellowship Review Committee of the Cancer Research Institute's Scientific Advisory Council, with the approval of the Institute's Board of Trustees, has named 13 new postdoctoral fellows from its October 2008 application round, awarding more than $1.89 million in research funding through the Irvington Institute Fellowship Program of the Cancer Research Institute.
The 13 young research scientists are conducting basic and tumor immunology laboratory investigations under the guidance of leading immunologists and tumor immunologists at distinguished academic institutions throughout the United States, including Whitehead Insitute for Biomedical Research, New York University School of Medicine, The Scripps Research Institute, Memorial Sloan-Kettering Cancer Center, and Yale University, among others.
Since the fellowship program's inception in 1971, 953 fellows have received valuable funding from the Cancer Research Institute. Many fellows have since gone on to become leaders in their field, including two who have won the Nobel Prize.
+++
Cancer Research Institute Postdoctoral Fellows Awarded in December 2008
Peter Beemiller, Ph.D., University of California, San Francisco, San Francisco, California, with Matthew F. Krummel, Ph.D.Project Title: Actin cytoskeletal regulation of the T-cell receptor signalosome
Micah J. Benson, Ph.D., Immune Disease Institute, Inc. and Harvard Medical School, Boston, Massachusetts, with Anjana Rao, Ph.D.Project Title: Discovery of factors regulating immunoglobulin mRNA alternative splicing
Alex Christopher Engel, Ph.D., University of California, Berkeley, Berkeley, California, with Greg M. Barton, Ph.D.Project Title: Mechanisms controlling localization and activation of intracellular Toll-like receptors
Hiroaki Ito, Ph.D., Benaroya Research Institute at Virginia Mason, Seattle, Washington, with Jessica A. Hamerman, Ph.D.Project Title: Regulation of dendritic cell responses by ITAM-containing signaling adapters
Rebecca Anna Johnson, Ph.D., The Skirball Instute for Biomolecular Medicine at the NYU Langone Medical Center, New York, New York, with David B. Roth, M.D., Ph.D.Project Title: Isolated recombination signals as novel mediators of genomic instability
Ralf M. Leonhardt, Ph.D., Yale University, New Haven, Connecticut, with Peter Cresswell, Ph.D.Project Title: Characterization of TAP- and tapasin-independent MHC class I-restricted melanoma epitopes
Haihui Lu, Ph.D., Whitehead Institute for Biomedical Research, Cambridge, Massachusetts, with Robert A. Weinberg, Ph.D.Project Title: Heterotypic interaction between tumor associated macrophage (TAM) and breast tumor during epithelial-mesenchymal transition (EMT)
Carsten Mim, Ph.D., Yale University, New Haven, Connecticut, with Vinzenz M. Unger, Ph.D.Project Title: Structural studies on BAR-proteins and their role in membrane remodeling
Ngozi Rosalin Monu, Ph.D., New York University Medical Center, New York, New York, with Eduardo S. Trombetta, Ph.D., PharmDProject Title: Mechanisms of antigen presentation by dendritic cells
Carles Ubeda Morant, D.V.M, Ph.D., Memorial Sloan-Kettering Cancer Center, New York, New York, with Eric G. Pamer, M.D.Project Title: Innate immune effect on intestinal microbial diversity
Read Pukkila-Worley, M.D., Massachusetts General Hospital, Boston, Massachusetts, with Eleftherios Mylonakis, M.D., Ph.D.Project Title: A Caenorhabditis elegans and Cryptococus neoformans model of the host-pathogen interaction
MacLean C. Sellars, Ph.D., New York University Medical Center, New York, New York, with Dan R. Littman, M.D., Ph.D.Project Title: Defining the transcription factor networks that control Th17 specification.
Kittichoat Tiyanont, Ph.D., Brigham and Women's Hospital, Boston, Massachusetts, with Stephen C. Blacklow, M.D., Ph.D. Project Title: Inhibitors of Notch signaling
More detailed descriptions of the fellows' research projects can be viewed at http://www.cancerresearch.org/programs/research/fellowship/fellows-2008-12.html. The Cancer Research Institute extends its congratulations to this latest group of postdoctoral fellows. The next deadline for application to the Institute's fellowship program is October 1, 2009.
About the Cancer Research InstituteThe Cancer Research Institute (CRI) is the world's only non-profit organization dedicated exclusively to the support and coordination of scientific and clinical efforts that will lead to the immunological treatment, control, and prevention of cancer. Guided by a world-renowned Scientific Advisory Council that includes five Nobel Prize winners and thirty members of the National Academy of Sciences, CRI supports cutting-edge cancer research at top medical centers and universities throughout the world. The Cancer Research Institute is ushering in a new era of scientific progress, hastening the discovery of effective cancer vaccines and other immune-based therapies that are providing new hope to cancer patients.
The Cancer Research Institute has one of the lowest overhead expense ratios among non-profit organizations, with the majority of its resources going directly to the support of its science, medical, and research programs. CRI has earned the coveted four out of four stars from Charity Navigator, an 'A' grade for fiscal disclosure and efficiency from the American Institute of Philanthropy, and top marks from other charity watchdog organizations. www.cancerresearch.org
RSS